Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    TopAbstracts in Hypertension 11/26/2008 - (DGNews)
    Potassium Loss Caused by Thiazides May Explain Higher Risk of Adult Diabetes - (DGNews)
    High Blood Pressure in Doctor's Office May Not Predict Heart Risks - (DGNews)
    TopAbstracts in Hypertension 11/19/2008 - (DGNews)
    Aliskiren Helps Elderly Patients Achieves Blood Pressure Control: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Hypertension
    • Minimizing Cardiovascular Risk in Patients With Dyslipidemia
    • Beta-Blockers in Hypertension - The Con Discussion
      Vaccination: A New Approach to RAAS Inhibition?
      Beta-Blockers in Hypertension - The Pro Discussion
      Which Anti-RAAS Shall We Use?

      Webcasts/CME archive

       Recent cases - Hypertension
        Aortic Dissection Type I in a Weightlifter with Hypertension: A Case Report
        Transient Left Ventricular Apical Ballooning and Exercise Induced Hypertension During Treadmill Exercise Testing: Is There a Common Hypersympathetic Mechanism?
        Dilation of Renal Artery Stenosis after Administration of Losartan
        Angioedema of the Tongue
        Primary Aldosteronism Caused by a Unilateral Adrenal Adenoma Accompanied by Autonomous Cortisol Secretion

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Omapatrilat Better Than Enalapril for Blood Pressure but Increases Angioedema Risk: Presented at ESC

        By Ed Susman
        Special to DG News

        BERLIN, GERMANY -- September 5, 2002 -- High risk hypertensive patients -- particularly those with diabetes -- appear to do better on the investigative vasopeptidase inhibitor omapatrilat than on the angiotensin-converting enzyme inhibitor enalapril, researchers reported at the 24th annual congress of the European Society of Cardiology.

        "Omapatrilat is consistently more efficacious than enalapril in reducing systolic blood pressure and achieving blood pressure control," said Michael A. Weber, MD, associate dean and professor of medicine at the State University of New York Health Science Center at Brooklyn.

        In a "clinical trials update" report, Dr. Weber said analysis of the OCTAVE (Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril) trial said that the drug does appear to cause more angioedema in the high-risk group of patients recruited for the trial.

        About 1.18 percent of patients taking omapatrilat developed angioedema, compared with about 0.6 percent of patients taking enalapril in the study. The angioedema episodes generally occurred early in the trial and new cases were rare after six months.

        Even in the patients who did suffer angioedema, Dr. Weber said the researchers observed no airway compromise or any need for mechanical intervention in those patients.

        He said that omapatrilat was, in particular, advantageous to patients who were diabetic and patients whose blood pressure could not be controlled by ACE inhibition.

        In the analysis of high-risk patients -- those with demonstrated atherosclerotic disease -- from the OCTAVE cohort, Dr. Weber and colleagues identified 2,371 patients who had previously had a myocardial infarction, angina pectoris, stroke or transient ischemic attack.

        The patients received either omapatrilat or enalapril, and their physicians were urged to seek blood pressure control in the study. Patients following randomization stayed on their assigned medication for 8 weeks. If they had not met the blood pressure goal of 140/90 after 8 weeks, they were then continued for 16 weeks, but were allowed to receive adjunctive prescription medication.

        Overall, patients talking omapatrilat reduced their blood pressure by about 3 to 4 mmHg. However, if a patient required more than two drugs to reach goal, the difference between omapatrilat and enalapril was nearly 6 mmHg. Dr. Weber said both differences were statistically significant.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send